title: [Effects of xinmaikang capsule on acute myocardial ischemia in coronary artery occlusion dogs].
abstract: OBJECTIVE
  To observe the preventive effect of xinmaikang capsule against acute myocardial ischemia in coronary artery occlusion dogs.
  
  
  METHODS
  25 healthy hybrids dogs, male and female, were randomly divided into control group (physiological saline solution), 40 mg/kg Di'aoxinxuekang Group, xinmaikang low doses (1.55 g/kg), median doses (3.10 g/kg) and high doses (6.20 g/kg) group, 5 dogs a group. The left downwards coronary arteries of dogs were ligated to establish the acute myocardial ischemia model. The blood gas analysis, myocardial enzyme detection, blood pressure,heart rate and epicardial electrogram recorded were detected before and after the stomach lavage. 240 min later, the myocardial tissues were stained with NBT technology to examine the sizes of infarction areas.
  
  
  RESULTS
  (1) Each dose of xinmaikang capsule could increase coronary artery blood flow (CBF) and reduce the coronary resistance (CVR) (P < 0.05 or P < 0.01). (2) The median and high doses of xinmaikang capsule could decrease myocardial oxygen consumption significantly (P < 0.05 or P < 0.01); (3) In the median and high doses of the xinmaikang capsule groups, the infarction areas decreased significantly (P < 0.01). (4) Serum lactate dehydrogenase (LDH) and Creatine phosphokinase (CPK) levels decreased significantly (P < 0.05 or P < 0.01) in all xinmaikang groups.
  
  
  CONCLUSIONS
  Xinmaikang capsule has the effect of anti-myocardial ischemia and can protect myocardial cells, which is a potential drug and precaution treatment for myocardial ischemia.
authors.affiliation: Medical College of Jinan University, Guangzhou 510632, China.
authors.forename: Ting-chun
authors.initials: TC
authors.lastname: Wang
authors.forename: Rong-hua
authors.initials: RH
authors.lastname: Zhang
authors.forename: Pan-pan
authors.initials: PP
authors.lastname: Wang
authors.forename: Ren-qiang
authors.initials: RQ
authors.lastname: Ma
authors.forename: Xiao-feng
authors.initials: XF
authors.lastname: Zhu
mesh_terms: D000208:Acute Disease; D000818:Animals; D002214:Capsules; D003326:Coronary Circulation / Q000187:drug effects; D003402:Creatine Kinase / Q000097:blood; D004195:Disease Models, Animal; D004285:Dogs; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal / Q000494:pharmacology* / Q000627:therapeutic use; D004562:Electrocardiography; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D045022:Lactate Dehydrogenases / Q000097:blood; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy / Q000473:pathology; D017202:Myocardial Ischemia / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D009206:Myocardium / Q000201:enzymology / Q000473:pathology; D010101:Oxygen Consumption / Q000187:drug effects; D008517:Phytotherapy; D010946:Plants, Medicinal / Q000737:chemistry*; D011897:Random Allocation
chemical_list: D002214:Capsules; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D045022:Lactate Dehydrogenases; D003402:Creatine Kinase